Kairos Pharma Acquires Exclusive Worldwide Rights to CL-273

Kairos Pharma has signed a binding strategic asset acquisition for exclusive worldwide rights to CL-273 from Orbimed and Torrey Pines Investment-backed Celyn Therapeutics.

2 Mar, 14:11 — 2 Mar, 14:11

Post Share

ℹOnly 1 source covers this story

Read at source (1 outlet)

Reuters2d ago

Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics - TradingView

Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics TradingView

Read full article →

PERSPECTA

PERSPECTA

Kairos Pharma Acquires Exclusive Worldwide Rights to CL-273

Read at source (1 outlet)

Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics - TradingView

Related Stories

Counterfeit Products Worth P237 Million Seized in Binondo, Manila

Albanian Foreign Exchange Market Update

EU Strategy for Shipping Industry Welcomed by Greek Shipowners

Greek Tourism Monitors Geopolitical Developments with Caution

PERSPECTA